US5266480A
(en)
*
|
1986-04-18 |
1993-11-30 |
Advanced Tissue Sciences, Inc. |
Three-dimensional skin culture system
|
US5219740A
(en)
*
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US6048729A
(en)
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6544771B1
(en)
|
1987-12-11 |
2003-04-08 |
Cell Genesys, Inc. |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
US6140111A
(en)
*
|
1987-12-11 |
2000-10-31 |
Whitehead Institute For Biomedical Research |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
US5591624A
(en)
*
|
1988-03-21 |
1997-01-07 |
Chiron Viagene, Inc. |
Retroviral packaging cell lines
|
US6133029A
(en)
*
|
1988-03-21 |
2000-10-17 |
Chiron Corporation |
Replication defective viral vectors for infecting human cells
|
US5716826A
(en)
*
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
US6645942B1
(en)
|
1988-04-28 |
2003-11-11 |
The Salk Institute For Biological Studies |
Somatic cell gene therapy
|
WO1990006997A1
(en)
*
|
1988-12-13 |
1990-06-28 |
United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Genetically engineered endothelial cells and use thereof
|
US5650148A
(en)
*
|
1988-12-15 |
1997-07-22 |
The Regents Of The University Of California |
Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
|
ATE174514T1
(de)
*
|
1989-01-23 |
1999-01-15 |
Chiron Corp |
Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
|
US7238673B2
(en)
|
1989-03-31 |
2007-07-03 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
JP3244696B2
(ja)
*
|
1989-06-13 |
2002-01-07 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー |
ヒト筋肉細胞の単離、増殖および分化
|
EP0897987B1
(de)
*
|
1989-10-24 |
2001-02-28 |
Chiron Corporation |
Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
|
AU7312891A
(en)
*
|
1990-02-12 |
1991-09-03 |
Board Of Regents, The University Of Texas System |
Satellite cell proliferation in adult skeletal muscle
|
US5817491A
(en)
*
|
1990-09-21 |
1998-10-06 |
The Regents Of The University Of California |
VSV G pseusdotyped retroviral vectors
|
US5618531A
(en)
*
|
1990-10-19 |
1997-04-08 |
New York University |
Method for increasing the viability of cells which are administered to the brain or spinal cord
|
WO1992015676A1
(en)
*
|
1991-03-08 |
1992-09-17 |
The Salk Institute For Biological Studies |
Somatic cell gene therapy
|
PT101031B
(pt)
*
|
1991-11-05 |
2002-07-31 |
Transkaryotic Therapies Inc |
Processo para o fornecimento de proteinas por terapia genetica
|
US6692737B1
(en)
|
1991-11-05 |
2004-02-17 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6054288A
(en)
*
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
US6063630A
(en)
*
|
1991-11-05 |
2000-05-16 |
Transkaryotic Therapies, Inc. |
Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
|
ES2126606T3
(es)
*
|
1991-11-15 |
1999-04-01 |
Univ California |
Terapia del sistema nervioso central mediante celulas modificadas geneticamente.
|
CA2117303C
(en)
*
|
1991-11-29 |
2000-10-17 |
Sunil Chada |
Anti-cancer immunotherapeutic vector constructs
|
US6297048B1
(en)
|
1992-02-04 |
2001-10-02 |
Chiron Corporation |
Hepatitis therapeutics
|
EP0630384A4
(de)
*
|
1992-02-28 |
1996-09-04 |
Brigham & Womens Hospital |
Methoden und verbindungen zur verhinderung der transplantat-abstossung.
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
US5591625A
(en)
*
|
1993-11-24 |
1997-01-07 |
Case Western Reserve University |
Transduced mesenchymal stem cells
|
US5656605A
(en)
*
|
1994-01-26 |
1997-08-12 |
Institute Of Molecular Biology, Inc. |
Device to promote drug-induced nerve regeneration
|
DE69531712T2
(de)
*
|
1994-04-25 |
2004-07-01 |
Japan Science And Technology Corp., Kawaguchi |
Hybridgel, das eine biologisch aktive Substanz sekretiert
|
US6150137A
(en)
|
1994-05-27 |
2000-11-21 |
Ariad Pharmaceuticals, Inc. |
Immunosuppressant target proteins
|
US5888814A
(en)
*
|
1994-06-06 |
1999-03-30 |
Chiron Corporation |
Recombinant host cells encoding TNF proteins
|
GB9419048D0
(en)
*
|
1994-09-20 |
1994-11-09 |
Watt Diana J |
Treatment of muscular disorders
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6689757B1
(en)
|
1996-02-12 |
2004-02-10 |
M.L. Laboratories Plc |
Methods for vaccination and vaccines therefor
|
US5842477A
(en)
*
|
1996-02-21 |
1998-12-01 |
Advanced Tissue Sciences, Inc. |
Method for repairing cartilage
|
FR2746109B1
(fr)
|
1996-03-12 |
1998-04-17 |
Rhone Poulenc Rorer Sa |
Milieu pour la conservation de materiel biologique
|
US6210664B1
(en)
*
|
1996-04-08 |
2001-04-03 |
New York University Medical Center |
Method for gene transfer to the central nervous system
|
AU765149B2
(en)
*
|
1996-04-08 |
2003-09-11 |
New York University Medical Center |
Method for gene transfer to the central nervous system
|
US6027721A
(en)
*
|
1996-05-20 |
2000-02-22 |
Cytotherapeutics, Inc. |
Device and method for encapsulated gene therapy
|
US5932779A
(en)
|
1996-06-10 |
1999-08-03 |
Millennium Pharmaceuticals, Inc. |
Screening methods for compounds useful in the regulation of body weight
|
US5830850A
(en)
*
|
1996-08-28 |
1998-11-03 |
Mount Sinai School Of Medicine Of The City Of New York |
Methods for the treatment of bone resorption disorders, including osteoporosis
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
GB9715085D0
(en)
|
1997-07-18 |
1997-09-24 |
Jahoda Amanda J |
Gene therapy vehicle
|
CA2308511C
(en)
|
1997-10-29 |
2016-01-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of transfected or transduced mammalian cells for treating bone pathologies
|
WO1999024578A2
(en)
|
1997-11-06 |
1999-05-20 |
Chiron S.P.A. |
Neisserial antigens
|
BR9906927A
(pt)
|
1998-01-14 |
2001-11-20 |
Chiron Spa |
Proteìnas de neisseria meningitidis
|
AU762472B2
(en)
|
1998-03-13 |
2003-06-26 |
University Of British Columbia, The |
Therapeutic chemokine receptor antagonists
|
CA2305787A1
(en)
|
2000-05-09 |
2001-11-09 |
The University Of British Columbia |
Cxcr4 antagonist treatment of hematopoietic cells
|
CA2245224A1
(en)
|
1998-08-14 |
2000-02-14 |
Jiang-Hong Giong |
Chemokine receptor antagonists and chemotherapeutics
|
JP2002506625A
(ja)
|
1998-03-19 |
2002-03-05 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
サイトカインレセプター共通γ鎖様
|
WO2001031019A2
(en)
|
1999-10-29 |
2001-05-03 |
Chiron Spa |
Neisserial antigenic peptides
|
EP2261347A3
(de)
|
1998-05-01 |
2012-01-11 |
Novartis Vaccines and Diagnostics, Inc. |
Antigene und Zusammensetzungen gegen Neisseria meningitidis
|
DE69938190T2
(de)
|
1998-10-15 |
2009-03-05 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
|
AU1231000A
(en)
*
|
1998-10-26 |
2000-05-15 |
University Of Massachusetts |
Treatment of skin with adenosine or adenosine analog
|
ATE519840T1
(de)
|
1998-12-16 |
2011-08-15 |
Novartis Vaccines & Diagnostic |
Menschliche cyclin-abhängige kinase (hpnqalre)
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
WO2000039302A2
(en)
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
EP2357192A1
(de)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
|
EP1119368A2
(de)
|
1999-03-03 |
2001-08-01 |
Biogen, Inc. |
Verfahren zür modulierung des fettstoffwechsels und lagerung
|
WO2000053743A1
(en)
|
1999-03-12 |
2000-09-14 |
Gpc Biotech, Inc. |
Methods and reagents for identifying synthetic genetic elements
|
US6328762B1
(en)
|
1999-04-27 |
2001-12-11 |
Sulzer Biologics, Inc. |
Prosthetic grafts
|
RU2245366C2
(ru)
|
1999-04-30 |
2005-01-27 |
Чирон С.Р.Л. |
Антиген neisseria, кодирующая его нуклеиновая кислота, их использование
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
US7396905B1
(en)
|
1999-05-21 |
2008-07-08 |
Mckeon Frank |
Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
EP2275559A3
(de)
|
1999-09-28 |
2011-03-23 |
Shire Human Genetic Therapies, Inc. |
Optimierte Boten-RNA (mRNA)
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US6951839B1
(en)
|
1999-11-30 |
2005-10-04 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
US8168178B2
(en)
|
1999-11-30 |
2012-05-01 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
MXPA02006433A
(es)
|
1999-12-30 |
2002-11-29 |
Harvard College |
Metodos y composiciones que se refieren a la modulacion del crecimiento de hepatocitos, diferenciacion de celulas plasmaticas o actividad de subgrupos de celulas t mediante la modulacion de la actividad de xbp-1.
|
DK1897555T3
(da)
|
2000-01-17 |
2014-10-13 |
Novartis Vaccines & Diagnostic |
Kompletteret OMV-vaccine mod meningococcus
|
US7368425B2
(en)
|
2006-03-24 |
2008-05-06 |
Chemokine Therapeutics Corp. |
Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
|
US20050059584A1
(en)
|
2002-08-16 |
2005-03-17 |
Ahmed Merzouk |
Novel chemokine mimetics synthesis and their use
|
US7378098B2
(en)
|
2000-04-12 |
2008-05-27 |
The University Of British Columbia |
CXC chemokine receptor 4 agonist peptides
|
WO2001082973A2
(en)
*
|
2000-04-28 |
2001-11-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
|
EP1290162A4
(de)
*
|
2000-05-17 |
2005-08-17 |
Univ Oregon Health Sciences |
Induktion von apoptose und hemmung des zellwachstums durch das 4.33 protein
|
EP1294949A4
(de)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
Menschlicher tumornekrosefaktor delta und epsilon
|
AU2001268633A1
(en)
*
|
2000-06-21 |
2002-01-02 |
Diadexus, Inc. |
Method of diagnosing, monitoring, staging, imaging and treating breast cancer
|
WO2002034916A2
(en)
*
|
2000-10-27 |
2002-05-02 |
Oregon Health And Science University |
Novel mutant igbp-3 molecules that do not bind to igfs, but retain their ability to functionally bind igfbp-3 receptor
|
NZ593617A
(en)
|
2000-10-27 |
2012-04-27 |
Novartis Vaccines & Diagnostic |
Nucleic acids and proteins from streptococcus groups A & B
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
EP1366058B1
(de)
|
2001-02-09 |
2011-01-26 |
Human Genome Sciences, Inc. |
Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
JP2004536579A
(ja)
|
2001-04-13 |
2004-12-09 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
血管内皮増殖因子2
|
JP3966819B2
(ja)
|
2001-05-24 |
2007-08-29 |
キム,スーギョン |
毛嚢に存在する新規の第2ケラチノサイト成長因子類似体
|
EP2280074A3
(de)
|
2001-07-05 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
|
WO2003004620A2
(en)
|
2001-07-05 |
2003-01-16 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
EP1900815B1
(de)
|
2001-07-12 |
2016-09-07 |
University of Massachusetts |
In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
|
CA2453183C
(en)
|
2001-07-12 |
2016-05-10 |
University Of Massachusetts |
In vivo production of small interfering rnas that mediate gene silencing
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
EP2002827A2
(de)
|
2001-12-05 |
2008-12-17 |
The Baylor College Of Medicine |
Verfahren und Zusammensetzungen zur Regulierung der Knochenbildung mittels Modulation des sympathischen Tonus
|
ES2386386T3
(es)
|
2001-12-12 |
2012-08-20 |
Novartis Vaccines And Diagnostics S.R.L. |
Inmunización contra Chlamydia trachomatis
|
US7049121B2
(en)
*
|
2001-12-20 |
2006-05-23 |
Applied Molecular Evolution |
Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
|
US6989261B2
(en)
*
|
2001-12-20 |
2006-01-24 |
Eli Lilly And Company |
Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
|
US7255874B1
(en)
|
2001-12-21 |
2007-08-14 |
Closure Medical Corporation |
Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
WO2004048552A2
(en)
|
2002-11-21 |
2004-06-10 |
Celltech R & D, Inc. |
Modulating immune responses
|
JP2006508665A
(ja)
*
|
2002-12-04 |
2006-03-16 |
アプライド モレキュラー エボリューション,インコーポレイテッド |
化学療法剤の活性を変化させるブチリルコリンエステラーゼ変異体
|
ES2565327T3
(es)
|
2003-01-14 |
2016-04-04 |
Dana Farber Cancer Institute |
Sensibilizador de terapia del cáncer
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
CA2524883C
(en)
|
2003-05-16 |
2014-07-22 |
Universite Laval |
Potassium-chloride cotransporter kcc2 modulation for treatment of pain
|
ES2357116T5
(es)
|
2003-06-02 |
2021-09-03 |
Univ Massachusetts |
Métodos y composiciones para mejorar la eficacia y especificad de FNAi
|
AU2004248136B2
(en)
|
2003-06-02 |
2011-09-15 |
University Of Massachusetts |
Methods and compositions for controlling efficacy of RNA silencing
|
WO2005004794A2
(en)
|
2003-06-09 |
2005-01-20 |
Alnylam Pharmaceuticals Inc. |
Method of treating neurodegenerative disease
|
US7595306B2
(en)
*
|
2003-06-09 |
2009-09-29 |
Alnylam Pharmaceuticals Inc |
Method of treating neurodegenerative disease
|
NZ544263A
(en)
|
2003-06-10 |
2009-04-30 |
Nsgene As |
Improved secretion of neublastin
|
DK1677735T3
(da)
|
2003-10-17 |
2014-10-27 |
Joslin Diabetes Center Inc |
Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
|
ATE460183T1
(de)
|
2003-10-20 |
2010-03-15 |
Nsgene As |
Viraler vektor zur verwendung in der in-vivo- gentherapie von morbus parkinson
|
AU2004291911A1
(en)
|
2003-11-14 |
2005-06-02 |
Children's Medical Center Corporation |
Self-cleaving ribozymes and uses thereof
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
CN1957082B
(zh)
|
2004-03-29 |
2014-09-17 |
株式会社嘉尔药物 |
新的半乳凝素9突变体蛋白质及其用途
|
ATE430763T1
(de)
|
2004-03-30 |
2009-05-15 |
Nsgene As |
Therapeutische verwendung des wachstumsfaktors nsg33
|
WO2005115435A2
(en)
*
|
2004-04-30 |
2005-12-08 |
Bas Medical, Inc. |
Methods and compositions for control of fetal growth via modulation of relaxin
|
ATE540973T1
(de)
|
2004-07-22 |
2012-01-15 |
Five Prime Therapeutics Inc |
Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
|
US20090136552A1
(en)
*
|
2004-07-30 |
2009-05-28 |
Mette Gronborg |
Growth factors nsg28, nsg30, and nsg32
|
CA2576193A1
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
WO2006089095A2
(en)
|
2005-02-17 |
2006-08-24 |
Biogen Idec Ma Inc. |
Treating neurological disorders
|
CA2626584A1
(en)
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
EP1945270B1
(de)
|
2005-11-09 |
2011-05-25 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen
|
CA2629715C
(en)
|
2005-11-18 |
2016-05-03 |
Glenmark Pharmaceuticals S.A. |
Anti-alpha2 integrin antibodies and their uses
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
CA2647728C
(en)
|
2006-03-31 |
2014-12-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
EP2013222B1
(de)
|
2006-04-28 |
2013-02-13 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression eines gens aus dem jc-virus
|
CA2915441A1
(en)
|
2006-05-11 |
2007-11-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the pcsk9 gene
|
BRPI0712034A2
(pt)
|
2006-05-19 |
2012-01-10 |
Alnylam Pharmaceuticals Inc |
modulação de rnai de aha e usos terapêuticos do mesmo
|
WO2007137220A2
(en)
|
2006-05-22 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
EP2839843B1
(de)
|
2006-05-25 |
2018-06-20 |
Biogen MA Inc. |
VLA-1-Antagonisten zur Verwendung bei der Behandlung von Schlaganfall
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
US20110206692A1
(en)
|
2006-06-09 |
2011-08-25 |
Novartis Ag |
Conformers of bacterial adhesins
|
US8664364B2
(en)
|
2007-01-24 |
2014-03-04 |
Carnegie Mellon University |
Optical biosensors
|
US8673859B2
(en)
|
2007-03-20 |
2014-03-18 |
New York University |
GM-CSF cosmeceutical compositions and methods of use thereof
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
US20100184823A1
(en)
|
2007-07-05 |
2010-07-22 |
Mark Aron Labow |
dsRNA For Treating Viral Infection
|
EP2617828B1
(de)
|
2007-12-10 |
2014-09-24 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
|
US20090176729A1
(en)
*
|
2007-12-14 |
2009-07-09 |
Alnylam Pharmaceuticals, Inc. |
Method of treating neurodegenerative disease
|
AU2009221775B2
(en)
|
2008-03-05 |
2015-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
JP2011523357A
(ja)
|
2008-05-06 |
2011-08-11 |
ジョスリン ダイアビーティス センター インコーポレイテッド |
褐色脂肪細胞分化を誘導するための方法および組成物
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
EP2690175B1
(de)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6
|
US20110287026A1
(en)
|
2008-09-23 |
2011-11-24 |
President And Fellows Of Harvard College |
Sirt4 and uses thereof
|
ES2740129T3
(es)
|
2008-09-25 |
2020-02-05 |
Alnylam Pharmaceuticals Inc |
Composiciones formuladas en lípidos y métodos de inhibición de la expresión del gen de suero amiloide A
|
EA036772B1
(ru)
|
2008-10-20 |
2020-12-18 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы для ингибирования экспрессии транстиретина
|
NZ606825A
(en)
|
2008-11-10 |
2014-10-31 |
Alexion Pharma Inc |
Methods and compositions for treating complement-associated disorders
|
JP5855462B2
(ja)
|
2008-12-10 |
2016-02-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
GNAQを標的としたdsRNA組成物および発現を阻害するための方法
|
WO2010080985A1
(en)
|
2009-01-08 |
2010-07-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
US20120021039A1
(en)
|
2009-01-23 |
2012-01-26 |
Nsgene A/S |
Expression of neuropeptides in mammalian cells
|
WO2010099019A1
(en)
|
2009-02-24 |
2010-09-02 |
Alexion Pharmaceuticals, Inc. |
Antibodies containing therapeutic tpo/epo mimetic peptides
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
CN102421900B
(zh)
|
2009-03-12 |
2015-07-22 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
|
US9487756B2
(en)
|
2009-03-20 |
2016-11-08 |
Mesoblast, Inc. |
Production of reprogrammed pluripotent cells
|
US9149024B2
(en)
|
2009-06-22 |
2015-10-06 |
Massachusetts Eye & Ear Infirmary |
Islet1 (Isl1) and hearing loss
|
WO2011050210A1
(en)
|
2009-10-21 |
2011-04-28 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
EP2498825B1
(de)
|
2009-11-09 |
2017-03-29 |
Genepod Therapeutics Ab |
Neues virales vektorkonstrukt zur neuronenspezifischen kontinuierlichen dopa-synthese in vivo
|
WO2011088163A1
(en)
|
2010-01-14 |
2011-07-21 |
President And Fellows Of Harvard College |
Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
|
US20130040853A1
(en)
|
2010-01-21 |
2013-02-14 |
Dana-Farber Cancer Institute Inc. |
Context Specific Genetic Screen Platform to Aid in Gene Discovery and Target Validation
|
EP3329924B1
(de)
|
2010-03-29 |
2021-05-05 |
Alnylam Pharmaceuticals, Inc. |
Dsrna-therapie für durch transthyretin (ttr) vermittelte augenamyloidose
|
EP2824111B1
(de)
|
2010-04-30 |
2017-03-22 |
Alexion Pharmaceuticals, Inc. |
Anti-C5A-Antikörper und Anwendungsverfahren dafür
|
EP2621512B1
(de)
|
2010-10-01 |
2016-04-06 |
NsGene A/S |
Verwendung von meteorin zur behandlung von allodynie, hyperalgesie, spontanen schmerzen und phantomschmerzen
|
WO2012051301A1
(en)
|
2010-10-12 |
2012-04-19 |
President And Fellows Of Harvard College |
Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
|
US8815942B2
(en)
|
2010-10-20 |
2014-08-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
|
US9539427B2
(en)
|
2010-11-08 |
2017-01-10 |
The Johns Hopkins University |
Methods for improving heart function
|
WO2012092299A1
(en)
|
2010-12-27 |
2012-07-05 |
Brown University |
Therapeutic and diagnostic methods involving biglycan and utrophin
|
WO2012094511A2
(en)
|
2011-01-05 |
2012-07-12 |
Rhode Island Hospital |
Compositions and methods for the treatment of orthopedic disease or injury
|
EP3388068A1
(de)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
|
CA2839711C
(en)
|
2011-06-21 |
2023-04-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
|
CN104105501B
(zh)
|
2011-09-05 |
2017-10-20 |
霍巴治疗公司 |
异常性疼痛、痛觉过敏、自发性疼痛、和幻痛的治疗
|
WO2013039996A1
(en)
|
2011-09-13 |
2013-03-21 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using fndc5
|
US10378060B2
(en)
|
2011-10-14 |
2019-08-13 |
Dana-Farber Cancer Institute, Inc. |
ZNF365/ZFP365 biomarker predictive of anti-cancer response
|
IN2014MN01680A
(de)
|
2012-02-13 |
2015-07-03 |
Gamida Cell Ltd |
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
EP2946013A1
(de)
|
2013-01-16 |
2015-11-25 |
Iowa State University Research Foundation, Inc. |
Tiefes intronisches ziel zur spleisskorrektur des spinalen muskelatrophiegens
|
EP2851086A1
(de)
|
2013-09-20 |
2015-03-25 |
Sanofi |
Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
|
WO2014128257A1
(en)
|
2013-02-22 |
2014-08-28 |
Sanofi |
Serpins: methods of therapeutic beta-cell regeneration and function
|
EP2769732A1
(de)
|
2013-02-22 |
2014-08-27 |
Sanofi |
Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
|
BR112015023108A8
(pt)
|
2013-03-13 |
2018-01-23 |
Geneweave Biosciences Inc |
sistema de acondicionamento de célula bacteriana, método para acondicionamento de uma molécula de ácido nucléico repórter, composição, método para detectar uma presença ou uma ausência de uma célula bacteriana em uma amostra, vetor, método para detectar um transcrito alvo em uma célula, método para detectar a presença de uma célula bacteriana em uma amostra e kit.
|
EP3008191A2
(de)
|
2013-06-13 |
2016-04-20 |
Shire Human Genetic Therapies, Inc. |
Virenproduktion auf messenger-rna-basis
|
DK3049521T3
(en)
|
2013-09-25 |
2019-04-23 |
Univ Cornell |
Compounds for inducing antitumor immunity and methods thereof
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
CA2944903A1
(en)
|
2014-04-24 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
CA2991750C
(en)
|
2014-07-24 |
2023-02-14 |
Massachusetts Eye & Ear Infirmary |
Rpgr gene therapy for retinitis pigmentosa
|
WO2016057367A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
WO2016057651A1
(en)
|
2014-10-09 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable il-2 dose regimen for treating immune disorders
|
CA2973878A1
(en)
|
2015-01-22 |
2016-07-28 |
University Of Massachusetts |
Cancer immunotherapy
|
EP3250588A1
(de)
|
2015-01-29 |
2017-12-06 |
Board of Trustees of Michigan State University |
Kryptische polypeptide und verwendungen davon
|
WO2016144673A1
(en)
|
2015-03-06 |
2016-09-15 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
|
US20180043034A1
(en)
|
2015-03-06 |
2018-02-15 |
Massachusetts Eye And Ear Infirmary |
Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene
|
US20160279207A1
(en)
|
2015-03-10 |
2016-09-29 |
University Of Massachusetts |
Targeting gdf6 and bmp signaling for anti-melanoma therapy
|
US20180104331A1
(en)
|
2015-05-11 |
2018-04-19 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
US20180140626A1
(en)
|
2015-05-14 |
2018-05-24 |
Joslin Diabetes Center, Inc. |
Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
|
WO2017021359A1
(en)
|
2015-08-03 |
2017-02-09 |
Myodopa Limited |
Systemic synthesis and regulation of l-dopa
|
WO2017066796A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
US20210106661A1
(en)
|
2015-10-29 |
2021-04-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
EP3377086B1
(de)
|
2015-11-19 |
2024-05-01 |
The Brigham and Women's Hospital, Inc. |
Lymphozytenantigen cd5-like(cd5l)-interleukin 12b (p40)-heterodimere in der immunität
|
EP3397282A4
(de)
|
2015-12-30 |
2019-08-07 |
Momenta Pharmaceuticals, Inc. |
Verfahren im zusammenhang mit biologika
|
CA3017757A1
(en)
*
|
2016-03-18 |
2017-09-21 |
Intrexon Corporation |
Compositions and methods for treatment of type vii collagen deficiencies
|
KR20190080825A
(ko)
|
2016-03-21 |
2019-07-08 |
다나-파버 캔서 인스티튜트 인크. |
T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도
|
US20190300864A1
(en)
|
2016-05-20 |
2019-10-03 |
Braingene Ab |
Destabilising domains for conditionally stabilising a protein
|
WO2018001858A1
(en)
|
2016-06-27 |
2018-01-04 |
University Of Copenhagen |
Tailored assembly of a modular bud polypeptide
|
CA3034643A1
(en)
|
2016-09-20 |
2018-03-29 |
Ellen Weisberg |
Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
|
EP3532638A4
(de)
|
2016-10-31 |
2020-07-29 |
University of Massachusetts |
Targeting von microrna-101-3p in der krebstherapie
|
EP3609577A4
(de)
|
2017-04-14 |
2021-03-24 |
University of Massachusetts |
Braune fettselektive adipokine
|
WO2018226685A2
(en)
|
2017-06-06 |
2018-12-13 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
|
US10806780B2
(en)
|
2017-06-28 |
2020-10-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
|
BR112020001703B1
(pt)
|
2017-07-27 |
2024-01-02 |
Alexion Pharmaceuticals, Inc |
Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
CN112912098A
(zh)
|
2018-06-01 |
2021-06-04 |
赛诺菲 |
用于治疗乙型肝炎病毒感染的组合疗法
|
FI3823665T3
(fi)
|
2018-07-19 |
2024-03-01 |
Regeneron Pharma |
BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä
|
KR20210093908A
(ko)
|
2018-10-23 |
2021-07-28 |
리제너론 파아마슈티컬스, 인크. |
Ny-eso-1 t 세포 수용체 및 이의 사용 방법
|
WO2020120649A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
|
JP2022515451A
(ja)
|
2018-12-27 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
アシネトバクター・バウマンニの検出のための、非複製的形質導入粒子及び形質導入粒子に基づくレポーター系
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
IT201900007060A1
(it)
|
2019-05-21 |
2020-11-21 |
St Superiore Di Sanita |
Cellule tumorali ingegnerizzate e loro usi
|
IT201900012540A1
(it)
|
2019-07-22 |
2021-01-22 |
Humanitas Mirasole Spa |
Inibitori di CHI3L1 e loro usi
|
BR112022001194A2
(pt)
|
2019-07-24 |
2022-06-07 |
Regeneron Pharma |
Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
|
US20220356234A1
(en)
|
2019-10-02 |
2022-11-10 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
EP4069291A1
(de)
|
2019-12-03 |
2022-10-12 |
Evotec International GmbH |
Interferon-assoziierte antigenbindende proteine und verwendungen davon
|
CA3163356A1
(en)
|
2019-12-03 |
2021-06-10 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use in treating hepatitis b infection
|
EP4085156B1
(de)
|
2019-12-31 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Quantitatives pcr-screening von induzierbaren prophagen aus bakterienisolaten
|
MX2022009137A
(es)
|
2020-01-24 |
2022-10-21 |
Regeneron Pharma |
Antígeno expresado preferentemente en receptores de linfocitos t de melanoma (prame) y sus métodos de uso.
|
US20210347888A1
(en)
|
2020-04-24 |
2021-11-11 |
Millennium Pharmaceuticals, Inc. |
Anti-cd19 antibodies and uses therof
|
WO2021226063A1
(en)
|
2020-05-05 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Car comprising cd28 zeta and cd3 zeta
|
AU2021340793A1
(en)
|
2020-09-14 |
2023-05-11 |
Vor Biopharma Inc. |
Single domain antibodies against cd33
|
EP4229222A2
(de)
|
2020-10-19 |
2023-08-23 |
Dana-Farber Cancer Institute, Inc. |
Keimbahnbiomarker einer klinischen reaktion und nutzen für eine immuncheckpoint-inhibitortherapie
|
WO2022104104A2
(en)
|
2020-11-13 |
2022-05-19 |
Dana-Farber Cancer Institute, Inc. |
Personalized fusion cell vaccines
|
MX2023007302A
(es)
|
2020-12-18 |
2023-09-04 |
Momenta Pharmaceuticals Inc |
Anticuerpos contra la integrina alfa 11 beta 1.
|
WO2022159793A2
(en)
|
2021-01-25 |
2022-07-28 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for identifying neuroendocrine prostate cancer
|
CN117425673A
(zh)
|
2021-04-09 |
2024-01-19 |
武田药品工业株式会社 |
靶向补体因子d的抗体和其用途
|
US20230018888A1
(en)
|
2021-04-26 |
2023-01-19 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2 antibodies and uses thereof
|
BR112023020365A2
(pt)
|
2021-04-26 |
2023-11-21 |
Millennium Pharm Inc |
Anticorpo anti-clec12a ou fragmento de ligação ao antígeno, método de tratamento de um câncer, composição farmacêutica, sequência de ácidos nucleicos, vetor, célula, e, método de tratamento de câncer
|
AU2022271212A1
(en)
|
2021-05-04 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
WO2022233989A1
(en)
|
2021-05-06 |
2022-11-10 |
Hoba Therapeutics Aps |
Prevention and treatment of chemotherapy-induced neuropathic pain
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
CN117999085A
(zh)
|
2021-06-09 |
2024-05-07 |
埃沃特克国际有限责任公司 |
用于治疗或预防冠状病毒感染的干扰素相关的抗原结合蛋白
|
CA3236038A1
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023104960A1
(en)
|
2021-12-10 |
2023-06-15 |
Hoba Therapeutics Aps |
Treatment of nociceptive pain
|
WO2023158732A1
(en)
|
2022-02-16 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
|
WO2023201238A1
(en)
|
2022-04-11 |
2023-10-19 |
Vor Biopharma Inc. |
Binding agents and methods of use thereof
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|